Balloon aortic valvuloplasty for severe aortic stenosis before urgent non-cardiac surgery
| Autor: | Flavien Vincent, Alessandro Cosenza, Thibault Pamart, Hugues Spillemaeker, Wassima Marsou, Tom Denimal, Dany Janah, Guillaume Schurtz, Gabin Legros, Sylvestre Maréchaux, A. Altes, David Aouate, Augustin Coisne, Julien Labreuche, Arnaud Sudre, Marjorie Richardson, Farid Nedjari, Cedric Delhaye, Eric Van Belle, Ludovic Appert, Gilles Lemesle, Sina Porouchani, Nicolas Debry, Habib Sylla, Basile Verdier |
|---|---|
| Přispěvatelé: | Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), Institut Coeur Poumon [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, Alliance française pour les essais cliniques cardio-vasculaires - French Alliance for Cardiovascular Trials (FACT), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Balloon Valvuloplasty
medicine.medical_specialty medicine.medical_treatment [SDV]Life Sciences [q-bio] Balloon Transcatheter Aortic Valve Replacement Risk Factors Clinical Research medicine Humans Retrospective Studies business.industry Incidence (epidemiology) Confounding Aortic Valve Stenosis medicine.disease Surgery Aortic valvuloplasty Stenosis Treatment Outcome Heart failure Non cardiac surgery Aortic Valve Cardiology and Cardiovascular Medicine business Mace |
| Zdroj: | EuroIntervention EuroIntervention, 2021, 17 (8), pp.E680+. ⟨10.4244/EIJ-D-20-01423⟩ |
| ISSN: | 1774-024X |
| Popis: | International audience; Background: Balloon aortic valvuloplasty (BAV) has been proposed as a therapeutic option in patients suffering from severe aortic stenosis (SAS) who need urgent non-cardiac surgery (NCS). Whether this strategy is better than medical therapy in this very specific population is unknown. Aims: We aimed to evaluate the clinical benefit of an invasive strategy (IS) with preoperative BAV in patients with SAS requiring urgent NCS. Methods: From 2011 to 2019, a registry conducted in two centres included 133 patients with SAS undergoing urgent NCS, of whom 93 underwent preoperative BAV (IS) and 40 a conservative strategy (CS) without BAV. All analyses were adjusted for confounding using inverse probability of treatment weighting (IPTW) (10 clinical and anatomical variables). Results: The primary outcome was MACE at one-month follow-up after NCS including mortality, heart failure, and other cardiovascular outcomes. In patients managed conservatively, occurrence of MACE was 20.0% (n=8) and death was 10.0% (n=4) at 1 month. In patients undergoing BAV, the occurrence of MACE was 20.4% (n=19) and death was 5.4% (n=5) at 1 month. Among patients undergoing conservative management, all events were observed after NCS while, in patients undergoing BAV, 12.9% (n=12) had events between BAV and NCS including 3 deaths, and 7.5% (n=7) had events after NCS including 2 deaths. In IPTW propensity analyses, the incidence of the primary outcome (20.4% vs 20.0%; OR 0.93, 95% CI: 0.38-2.29) and three-month survival (89.2% vs 90.0%; IPTW-adjusted HR 0.90, 95% CI: 0.31-2.60) were similar in both groups. Conclusions: Patients with SAS managed conservatively before urgent NCS are at high risk of events. A systematic invasive strategy using BAV does not provide a significant improvement in clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|